Skip to main content

Inauguration of Real World Evidence Collaboration between Karolinska Institutet and the American Headquarter of MSD

Pressmeddelande   •   Nov 16, 2016 14:02 CET

On the occasion of initiating a long-term collaborative agreement between Karolinska Institutet and the headquarter of MSD you are kindly invited to join us for the inauguration ceremony on Monday November 21st, 2016. The ceremony will provide an opportunity to learn on reason and scope of the collaboration, as well as an opportunity to interview leading scientists and actors within the collaboration.

The agreement brings a five-year collaborative commitment between Karolinska Institutet and MSDs Headquarter, Merck & Co., Inc. The focus of the collaboration is utilization of real world evidence, and may also include clinical studies. The overall goal is to address clinically important research questions and to describe patient management in order to improve patient outcomes and quality of care. This collaboration will constitute a significant intellectual knowledgebase as well as international investment to Swedish life science. During the first year the total investment will amount to 10 million SEK, decisions on investments during the rest of the collaboration period will be taken continuously by a steering group.

The inauguration will take place in the MSD Office, in English.

Agenda

Moderator: Dr. Anna Nilsson Vindefjärd, Secretary General of of Research!Sweden 

14.00 Welcoming remarks – Mr. Ulf Janzon, acting CEO, MSD Sweden

14.10 Value of the agreement for Karolinska Institutet and beyond – Professor Alexander

von Gabain, Deputy Vice-Chancellor (for Innovation and Commercial Outreach), Karolinska Institutet, shares his view of what value the agreement will bring to

research at KI

14.20 Value of the agreement for Merck & Co., Inc. and beyond – Dr. Susan Shiff, Head of CORE, Merck & Co., Inc. shares her view of what value the agreement will bring to

R&D at Merck & Co., Inc.

14.30 Collaboration for the future – Professor Anders Gustavsson, Dean of Research,

Karolinska Institutet, shares his view on the importance of the agreement for research and healthcare for the future

14.40 Swedish registry setting – Professor Tomas Jernberg, Karolinska Institutet, and

registry holder of Swedeheart, shares an introduction to the Swedish wealth of data

and how it may be utilized

14.55 Tying the Ribbons of Collaboration Swedish fika (coffee & cake) will be served

15.00 Time for interviews (please book interviews in advance)

About MSDFor 125 years, MSD has been a global health care leader working to help the world be well. MSD is known as Merck & Co. Inc in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.msd.se and connect with us onTwitter.

Bifogade filer

PDF-dokument